content_image/241723.jpg content_image/241721.jpg
## Notes to the Consolidated Financial Statements for the Year Ended 30 June 2014 

<img src='content_image/241723.jpg'>

* Prepaid clinical trials - The Company announced on 3 June 2013 that it had committed to moving its non-small cell lung cancer therapeutic, into clinical development. The Company is using European-based clinical research organisation Clinical Trials Group (CTGCRO) to manage both the initial clinical development and trials. The Company made prepayments in the September quarter 2013 in order to secure favourable commercial terms with CTGCRO for the conduct of the trials. 

## NOTE 11: CONTROLLED ENTITIES 

## (a) Controlled entities: 

<img src='content_image/241721.jpg'>

## (b) Controlled entities acquired or disposed: 

No controlled entities were acquired or disposed during the financial year. 

